Idarubicin Versus High Dose Daunorubicin in Acute Myelogenous Leukemia (AML)
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this non-inferiority study is to compare the effectiveness of two induction
chemotherapy regimens (cytarabine plus idarubicin [AI] versus cytarabine plus high-dose
daunorubicin [AD]) in AML. The effectiveness will be evaluated in terms of complete remission
(CR) rate.